In short
- Brussels now rules by October 13. The European Commission pushed back its Phase 1 deadline on Kimberly-Clark’s acquisition of Kenvue from September 29 to October 13, 2026, the automatic consequence of the buyer filing a remedy package.
- The remedies are confidential. The Commission declined to describe what was offered, in line with its standard policy, and reporting on the filing rests on people familiar with the matter rather than a published text.
- Period care is the acknowledged problem. Australia’s regulator already forced the sale of Kenvue’s Carefree and Stayfree brands because the two companies are two of only three significant suppliers in that category.
- China is now the slowest gate, not Europe. Beijing’s competition authority moved the deal off the simplified track into a full review, which pushes the practical closing question past the initial November 2, 2026 long stop date.
- Retail buyers face a $32 billion supplier. The combined group would carry roughly $32 billion in annual net revenue and about $7 billion in adjusted EBITDA on the companies’ own projections, changing the arithmetic in every household and personal care category review.
Kimberly-Clark has put a remedy package in front of European Union competition regulators in an attempt to clear the last major hurdle standing between it and Kenvue, the Tylenol and Listerine owner it agreed to buy for $48.7 billion in November 2025. The filing triggered an automatic extension of the Commission’s first-phase deadline to October 13, 2026, from September 29.
The move was reported on September 23 and matters far beyond the two balance sheets involved. If Brussels accepts the concessions, the deal creates one of the largest suppliers of everyday household, personal care and over-the-counter health products in the world, and it does so at a moment when grocers and pharmacy chains across Europe and North America are already fighting for margin. If Brussels refuses, a four-month in-depth investigation opens and the transaction slides into 2027.
What exactly did Kimberly-Clark file in Brussels?
Kimberly-Clark submitted commitments intended to resolve the competition concerns the Commission had identified during its preliminary review. The Commission confirmed that remedies had been offered and that its decision deadline had shifted to October 13, but it did not publish the substance.
That silence is procedure, not evasion. The Commission’s settled practice is to withhold the content of a remedy proposal while it is being assessed, because the package is still subject to change and because it will be shown to third parties under confidentiality. What is known about the shape of the offer comes from people familiar with the discussions, who indicated the company was willing to sell assets rather than accept behavioural conditions.
The Commission’s next step is a market test. Case teams circulate a non-confidential description of the commitments to rivals, customers and, in consumer goods cases, to large retail buyers, and ask whether the proposed divestiture would genuinely restore the competition the merger removes. Their answers shape what happens on October 13.
Three outcomes are on the table
The Commission can clear the deal in Phase 1 subject to the commitments, which is the outcome reporting from The Capitol Forum suggests Brussels is expected to reach. It can come back and demand a wider package, which would extend the clock again. Or it can decide the remedies do not go far enough and open a full Phase 2 investigation lasting roughly four months.
Phase 2 is not a refusal, but for a deal already ten months past announcement it is expensive. It would force Kimberly-Clark to negotiate an extension of the merger agreement’s outside date and would leave Kenvue running as a standalone public company through another reporting cycle.
Why does the October 13 deadline matter so much?
The date is the last realistic window in which this deal closes on its original timetable. Kimberly-Clark has guided to completion in the second half of 2026 since the deal was signed, and the merger agreement carries an initial long stop date of November 2, 2026, extendable to May 3, 2027.
An October 13 Phase 1 clearance with conditions leaves just under three weeks to satisfy the remaining conditions. A Phase 2 referral consumes the initial long stop date outright and pushes the parties into the extension, which is exactly the pattern visible in the EU’s parallel review of JD.com’s Ceconomy bid, where a retail acquisition has spent months in Brussels over conditions rather than over the principle of the transaction.
There is a second reason the date carries weight. Divestiture remedies in consumer goods are only as good as the buyer who takes the assets, and the Commission increasingly wants a purchaser identified before it signs off rather than afterwards. A short runway to October 13 means Kimberly-Clark is likely already shopping the relevant brands.
What Kimberly-Clark has already cleared
The regulatory picture is further along than the Brussels headline suggests. Shareholders on both sides approved the transaction on January 29, 2026, with Kimberly-Clark holders authorising the share issuance and Kenvue holders adopting the merger agreement. The waiting period under the US Hart-Scott-Rodino Act expired on February 4, 2026, meaning the American antitrust gate is closed.
Kimberly-Clark has also secured clearance under the EU’s Foreign Subsidies Regulation, the separate Brussels screen that examines whether non-EU state support distorts a European acquisition. That removes one of the two independent European vetoes. Only the merger review remains.
How did the transaction reach this point?
The deal has been in the regulatory system for the better part of a year, and the sequence explains why an October date in Brussels now carries so much weight.
| Date | Event | Significance |
|---|---|---|
| November 3, 2025 | Kimberly-Clark agrees to acquire Kenvue for $48.7 billion | Cash-and-stock offer at about a 46 percent premium |
| January 29, 2026 | Both shareholder bases approve | Removes the equity-approval condition |
| February 4, 2026 | US Hart-Scott-Rodino waiting period expires | American antitrust gate closes without conditions reported |
| July 28, 2026 | Kimberly-Clark notifies the Australian regulator | Files already offering a period care divestiture |
| August 2026 | South Africa clears conditionally | Second jurisdiction approves with conditions |
| Early September 2026 | Australia clears, conditional on selling Carefree and Stayfree | First published remedy defines the template |
| September 22 to 23, 2026 | Remedies filed in Brussels; deadline moves to October 13 | Phase 1 extension triggered automatically |
| November 2, 2026 | Initial long stop date | Extendable to May 3, 2027 |
Two features of that timeline stand out. The first is that the company has volunteered period care divestitures rather than resisted them, which is the behaviour of a buyer that wants a clean Phase 1 outcome in every jurisdiction and has priced the carve-out into the deal model.
The second is that the United States, the largest single market for both companies, cleared without reported conditions more than seven months ago. The remaining friction sits entirely outside the American market, in Europe and in China, which is unusual for a transaction between two US-listed companies and reflects how differently period care market structure looks jurisdiction by jurisdiction.
Which product overlaps actually worry regulators?
The two portfolios look complementary at a glance, which is precisely why the deal was pitched as a combination rather than a consolidation. Kimberly-Clark sells tissue, diapers and adult and feminine hygiene. Kenvue sells over-the-counter medicines, skin health and oral care. Most of the shelf does not collide.
The exception is period care, and it is not a marginal one. Regulators in more than one jurisdiction have identified the same overlap, and it is the only category where both companies hold genuinely significant positions in the same products.
| Category | Kimberly-Clark side | Kenvue side | Competitive overlap |
|---|---|---|---|
| Period care (pads, tampons, liners) | U by Kotex | Carefree, Stayfree | Direct, and the basis of the Australian condition |
| Facial and bath tissue | Kleenex | None | None |
| Baby diapers and wipes | Huggies | None material | None identified publicly |
| Oral care | None | Listerine | None |
| Skin health | None | Neutrogena, Aveeno | None |
| Over-the-counter medicines | None | Tylenol | None |
| First aid | None | Band-Aid | None |
Period care is a three-supplier market
Australia’s competition regulator set out the structural problem plainly. Kimberly-Clark and Kenvue are two of the three major suppliers of period care products in the country, with the third being Essity, which sells the Libra and TOM Organic brands. Merging two of three leaves a duopoly, and the regulator was not prepared to allow it.
The commissioner’s finding was direct: without the divestiture of the Carefree and Stayfree brands, the acquisition could substantially lessen competition in the supply of period care products in Australia. That is the language of a regulator that has already done the counterfactual and does not intend to be argued out of it.
European market structure is not identical to Australia’s, and Brussels runs its own analysis on its own geographic markets. But the category logic travels. Any jurisdiction where both Kotex-branded and Carefree or Stayfree products hold meaningful share is a jurisdiction where a remedy is the likely price of clearance.
Where the portfolios barely touch
Outside period care, the case for intervention thins out quickly. The Commission’s preliminary view, as reported, was that the broader overlap between the two portfolios did not raise significant competition concerns. Tylenol does not compete with Kleenex. Huggies does not compete with Listerine.
That asymmetry is what makes a Phase 1 clearance with conditions the most plausible outcome. The problem is narrow, well understood, and fixable with a sale. Regulators reserve Phase 2 for cases where the theory of harm is contested or the remedy is untested, and neither applies here.
What has Australia already forced the deal to give up?
Australia is the clearest window into what a European remedy will look like, because its process is finished and its reasoning is public. Kimberly-Clark notified the Australian Competition and Consumer Commission on July 28, 2026, and did so already offering an undertaking to divest Kenvue’s period care business in Australia and New Zealand, an acknowledgement of the overlap rather than a concession extracted under pressure.
The regulator cleared the transaction in early September on the condition that the Carefree and Stayfree period care brands be divested in Australia to a purchaser the regulator approves. Documentation of undertakings of this type is filed on the regulator’s public mergers register, which is where the eventual buyer will first become visible.
The pattern is familiar from retail and consumer transactions elsewhere. Regulators rarely block deals outright when a discrete overlap can be carved out; they carve it out and then police the buyer. It is the same mechanism at work in remedy packages in retail mergers reviewed by the UK’s competition authority, where a small number of local problem sites decide a national transaction.
South African regulators granted conditional approval in August 2026. Between Australia, South Africa and the pending European decision, three jurisdictions have now concluded that the deal is approvable with surgery rather than objectionable in principle.
Where does the rest of the world stand?
| Jurisdiction | Status | Key date | Condition attached |
|---|---|---|---|
| United States (HSR) | Cleared | Waiting period expired February 4, 2026 | None reported |
| Shareholders (both companies) | Approved | January 29, 2026 | Not applicable |
| South Africa | Conditionally approved | August 2026 | Conditions not detailed publicly |
| Australia (ACCC) | Conditionally approved | Cleared early September 2026 | Divest Carefree and Stayfree |
| EU Foreign Subsidies Regulation | Cleared | Secured ahead of the merger decision | None reported |
| EU merger control | Phase 1, remedies filed | Decision due October 13, 2026 | Under assessment |
| China (SAMR) | Full review after refiling | No published deadline | Under assessment |
China is now the slowest gate
Beijing’s State Administration for Market Regulation asked the parties to withdraw their original simplified-track filing and refile under the normal review procedure, which moved the deal into an in-depth phase. Simplified-track filings in China are designed for transactions with no meaningful overlap, and a request to refile is a signal that the authority does not accept that characterisation.
Reporting from ION Analytics indicated the extended Chinese review is not connected to a separate diaper-sector inquiry, which removes one theory about the delay. The Capitol Forum has separately noted that a vacancy at the top of the agency may be contributing to slower merger decisions generally.
For a transaction of this size, China is a required approval rather than an optional one, and its timetable is not published. That is the single largest source of uncertainty in the closing calendar, and it is why an October 13 clearance in Brussels does not by itself deliver a closed deal.
The long stop date sets the real clock
The merger agreement’s initial outside date is November 2, 2026, with an extension available to May 3, 2027. The gap between those two dates is the negotiating room the parties built in precisely for a scenario like this one.
Investors should read an extension as a procedural event rather than a distress signal. What would change the risk assessment is a Phase 2 referral in Brussels combined with a Chinese review still open in the first quarter of 2027, because that combination puts real pressure on the May 2027 backstop.
What does a bigger supplier mean for retailers?
On the companies’ own projections, the combined business would generate roughly $32 billion in annual net revenue and about $7 billion in adjusted EBITDA on a 2025 basis. Kenvue alone recorded approximately $15.5 billion in net sales, about $1.8 billion in operating income and roughly $1.0 billion in net income for the twelve months ended December 29, 2024.
For a grocery or pharmacy buyer, scale of that kind changes the annual category review from a negotiation between a retailer and several mid-sized suppliers into a negotiation with one very large counterparty that shows up in six or seven aisles at once. That is a structural shift in leverage, and it happens whether or not the period care remedy is accepted.
Shelf space and slotting leverage
The practical mechanism is cross-category bundling. A supplier present in tissue, diapers, pain relief, mouthwash and skin care can offer a retailer a combined trade-spend package that no single-category rival can match, and can make the volume commitment in one aisle contingent on space in another.
Retailers who manage this well do so through discipline in planograms and slotting fees, holding category decisions separate so that strength in one does not silently buy facings in another. Retailers who manage it badly discover at the next reset that a single supplier has quietly taken an extra shelf.
Private label as the retailer’s counterweight
Own-brand programmes are the standard answer, and they are more credible in some of these categories than others. Private label competes effectively in facial tissue, bath tissue and period care, where the product is well understood and the manufacturing base is broad.
It competes far less effectively against Tylenol or Listerine, where brand trust in an over-the-counter health product is the purchase driver and where switching a shopper to an own-brand analgesic is a slower project than switching them to own-brand paper towels. The merged portfolio is deliberately weighted toward the categories where private label struggles.
How does the deal reshape the e-commerce shelf?
The online implications are different from the in-store ones, and they are easy to miss because the categories involved look unglamorous. Household paper, diapers, analgesics and mouthwash are among the highest-frequency replenishment purchases in online grocery, and replenishment is where subscription mechanics and search defaults do most of the work.
A supplier that owns strong brands across several replenishment categories at once is better placed to win the default slot in a basket-building flow: the recommended bundle, the reorder prompt, the subscribe-and-save page. None of that requires new pricing power, only breadth, and breadth is exactly what the merger delivers.
Retail media budgets consolidate too
Retail media is the practical channel through which supplier scale becomes online visibility. Advertising commitments on a grocer’s or marketplace’s own network are negotiated centrally and increasingly at portfolio level, not brand by brand.
A combined Kimberly-Clark and Kenvue would enter those conversations with a single budget spanning tissue, baby, period care, oral care, skin health and over-the-counter medicines. Competing mid-sized suppliers in any one of those categories cannot match that commitment, and retail media inventory is allocated to the bidder who can.
Marketplace and third-party seller effects
Over-the-counter health products and personal care are heavily traded by third-party sellers, and brand owners have spent years tightening control over who lists them. Consolidating two brand portfolios under one owner consolidates the enforcement function as well.
Sellers who source these brands through distributors should expect authorised-reseller policies to be harmonised after closing, typically toward whichever of the two regimes was stricter. That is a quiet but material change for grey-market listings and for arbitrage sellers in health and beauty.
The divested brands become the interesting online asset
If Carefree and Stayfree change hands in multiple markets, their new owner inherits established shelf presence with no legacy digital commitments. Whether that buyer is a private equity platform, a regional hygiene specialist or a competitor such as Essity will determine whether the brands are defended online or harvested.
Retailers negotiating period care terms in 2027 should therefore treat the category as genuinely contestable for the first time in years. A newly independent challenger brand under pressure to prove itself is usually the most aggressive promotional partner on the shelf.
Will shoppers see higher prices?
The honest answer is that a merger of this kind rarely produces a visible price move in either direction, and the mechanisms that would raise prices are precisely the ones regulators are testing now.
Where the merger removes a genuine competitor, as in period care, the remedy is designed to prevent a price effect by putting the overlapping brands in independent hands. Where it does not remove a competitor, the merger does not give the combined firm new pricing power; Kleenex is not priced more freely because the same owner also sells Tylenol.
The likelier consumer-facing effects are quieter. Synergy targets in a deal of this size are typically delivered through procurement, manufacturing footprint and trade-spend efficiency, and the last of those can show up as fewer or shallower promotions rather than higher list prices. Pack architecture is the other lever, and shoppers have learned to watch for it after repeated rounds of pack size reductions across household and personal care.
There is also a reason for caution about assuming savings reach the shelf at all. Across the retail sector this year, corporate windfalls have consistently ended up funding balance-sheet priorities rather than consumer prices, a pattern documented in how windfall gains rarely reach shelf prices.
What are the biggest risks still attached to the deal?
Regulatory timing is the risk investors are pricing this month, but it is not the only one, and it may not be the largest over a multi-year horizon.
Tylenol litigation is the open-ended exposure
Kenvue carries litigation risk tied to acetaminophen, the active ingredient in Tylenol, including claims linking prenatal use to autism. Medical experts have publicly pushed back on the scientific basis for those claims, and no finding of liability follows from the existence of a claim.
What matters commercially is that the exposure is unquantified and that it is now being acquired rather than merely held. Reporting on the transaction has also flagged international talc claims as part of the inherited legal picture. Kimberly-Clark agreed to pay a premium of roughly 46 percent to Kenvue’s prior closing price, valuing the equity at about $21.01 per share through a mix of $3.50 in cash and 0.14625 Kimberly-Clark shares, and it did so with that litigation already public.
Integration and brand stewardship
Kenvue was separated from Johnson & Johnson in 2023 and has spent its short independent life rebuilding commercial capability. Folding it into a paper and hygiene business with a different operating rhythm is not a routine bolt-on, and the categories that justify the premium are the ones most sensitive to marketing execution.
Retail buyers have a direct stake in how that goes. Supplier reorganisations reliably produce service disruption, and an availability problem in a top-selling analgesic during a winter cold season is a retailer problem before it is a supplier problem.
How should retail and e-commerce teams prepare before October 13?
The useful preparation is unglamorous and can be done in the next two weeks.
- Identify your exposure by category. Pull the share of category revenue that sits with each company today, separately, and then combined. The combined number is the one that matters in your next negotiation.
- Assume the period care brands change hands. In any market with a remedy, Carefree and Stayfree will have a new owner with a new commercial team, new terms and possibly a weaker supply chain in the transition. Build the contingency now.
- Separate your category reviews in time. If tissue, baby, period care and over-the-counter health all come up for review in the same quarter, a single supplier can trade across them. Staggering the calendar removes that option.
- Refresh own-brand readiness in the paper and period care aisles. Those are the categories where a credible alternative is achievable on a realistic timeline.
- Watch the purchaser approval, not just the clearance. The identity and strength of the divestiture buyer determines whether the remedy actually preserves competition in your market.
What happens next?
The immediate sequence is short. The Commission completes its market test, weighs the responses from rivals and retail customers, and issues a decision on or before October 13, 2026. The most widely expected outcome, on current reporting, is clearance in Phase 1 subject to commitments.
After that, attention moves east. China’s full review has no published deadline, and it is the approval most likely to determine whether the transaction closes inside the initial November 2, 2026 long stop date or runs into the extension to May 3, 2027.
For retailers, neither date changes the strategic conclusion. A supplier of roughly $32 billion in annual revenue is being assembled across the household, personal care and over-the-counter health aisles, and the only question still open in Brussels is how much of the period care shelf gets handed to somebody else on the way.
Frequently asked questions
When will the EU decide on the Kimberly-Clark Kenvue deal?
The European Commission’s Phase 1 decision is due on or before October 13, 2026. That date replaced an earlier September 29 deadline and moved automatically when Kimberly-Clark filed a remedy package, which adds time for the Commission to assess and market-test the commitments.
What remedies did Kimberly-Clark offer the European Commission?
The Commission has not published them. It declined to give details in line with its standard policy of keeping remedy proposals confidential while they are under assessment. Reporting based on people familiar with the matter indicates the company was prepared to divest assets rather than offer behavioural commitments.
Why did Australia make Kimberly-Clark sell Carefree and Stayfree?
Because Kimberly-Clark and Kenvue are two of only three significant suppliers of period care products in Australia, alongside Essity with its Libra and TOM Organic brands. The regulator concluded that without divesting Carefree and Stayfree, the acquisition could substantially lessen competition in that category, and required a sale to a purchaser it approves.
How much is Kimberly-Clark paying for Kenvue?
The transaction was announced in November 2025 at a value of $48.7 billion. Kenvue holders receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share, which valued the stock at roughly $21.01 at announcement, a premium of about 46 percent to the prior close.
Could the deal still be blocked?
An outright prohibition looks unlikely on current reporting, because the competition concern is confined to one category and is fixable by divestiture. The realistic downside is delay rather than blockage: Brussels could open a four-month Phase 2 investigation, and China’s full review has no published deadline.
What does the merger mean for grocery and pharmacy buyers?
It creates a counterparty with roughly $32 billion in annual net revenue present across tissue, baby, period care, oral care, skin health and over-the-counter medicines. That allows cross-category trade-spend bundling, so buyers should keep category reviews separated in time and refresh own-brand alternatives in the aisles where private label is genuinely competitive.
Will Tylenol, Listerine or Huggies prices change after the deal closes?
There is no basis to expect a direct price increase in those brands, because none of them overlaps with a product the other company sells. Synergy delivery in transactions of this size more often shows up as reduced promotional depth or changes to pack sizes than as higher list prices.
Which approvals has the deal already received?
Shareholders of both companies approved it on January 29, 2026. The US Hart-Scott-Rodino waiting period expired on February 4, 2026. South Africa granted conditional approval in August 2026, Australia cleared it conditionally in early September 2026, and Kimberly-Clark has separately obtained EU Foreign Subsidies Regulation clearance.
What is the deadline for the deal to close?
The merger agreement carries an initial long stop date of November 2, 2026, which can be extended to May 3, 2027. Kimberly-Clark has guided to completion in the second half of 2026, but the open Chinese review makes the extension a realistic scenario.